Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allows for cancer detection, monitoring, and assessing treatment.
The last earnings update was 51 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Biomark Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Biomark Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Biomark Diagnostics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Biomark Diagnostics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Biomark Diagnostics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
Take a look at our analysis of 20B’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Biomark Diagnostics's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomark Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Biomark Diagnostics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Biomark Diagnostics's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Biomark Diagnostics's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Biomark Diagnostics is high growth as no earnings estimate data is available.
Unable to determine if Biomark Diagnostics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Biomark Diagnostics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Biomark Diagnostics's finances.
The net worth of a company is the difference between its assets and liabilities.
Biomark Diagnostics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Biomark Diagnostics has no long term commitments.
This treemap shows a more detailed breakdown of
Biomark Diagnostics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Biomark Diagnostics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Rashid Ahmed Bux, B.Sc., MBA, is the Founder of BioMark Technologies Inc., a bio pharm business, which has achieved Phase III status in an unprecedented 3 years and has been it Chief Executive Officer since June 19, 2014. Mr. Bux serves as Chief Executive Officer and President of Biomark Diagnostics Inc. He has more than 20 years of business management at the senior level. He was co-founder and Chief Operating Officer of Optima Health and KKT Spinecentres a developer and operator of spinal treatment centers located in Germany, China, Taiwan, UAE, Canada and India. He was President and Founder of Homeworks Inc. a subsidiary of BC Gas, the natural gas distributor in British Columbia, Canada. He servers on the board of two nternational health related companies and provides advisory services to African nations principally in East Africa. He has extensive contacts in the medical sectors on a global basis. He has been a Director of Biomark Diagnostics Inc. since June 19, 2014. He was inducted in the distinguished Phi Kappa Phi honorary for his outstanding educational achievement. He earned a Bachelor of Science in Business Administration with concentration in three areas from the Miami University in Ohio. He has the degree in Master of Business Administration from the University of Western Ontario where he earned several distinguished scholarships. He was a student at Nairobi University prior to obtaining a scholarship to attend Miami University.
Rashid's compensation has been consistent with company performance over the past year.
Rashid's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Biomark Diagnostics management team is less than 2 years, this suggests a new team.
CTO & Director
CFO & Project Director
Chief Scientific Officer
Chief Financial Officer of US
Principal Scientific Advisor
Board of Directors Tenure
Average tenure of the
board of directors in years:
The tenure for the Biomark Diagnostics board of directors is about average.
The Biomark Diagnostics (FRA:20B) Share Price Is Down 69% So Some Shareholders Are Wishing They Sold
Biomark Diagnostics Inc (FRA:20B) has rebounded strongly over the last week, with the share price soaring 140%. … Biomark Diagnostics hasn't yet reported any revenue yet, so it's as much a business idea as a business. … But with the share price diving 32% per year, over 3 years, it's probably fair to say that some shareholders no longer believe the company will succeed
Biomark Diagnostics Inc (FRA:20B): How Does It Impact Your Portfolio?
A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … How 20B's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … However, this is the opposite to what 20B’s actual beta value suggests, which is higher stock volatility relative to the market.
Should You Be Concerned About Biomark Diagnostics Inc's (FRA:20B) Shareholders?
This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: Institutional ownership in 20B is not at a level that would concern investors.
Was Biomark Diagnostics Inc's (FRA:20B) Earnings Growth Better Than The Industry's?
When Biomark Diagnostics Inc's (DB:20B) announced its latest earnings (31 December 2017), I wanted to understand how these figures stacked up against its past performance. … The two benchmarks I used were Biomark Diagnostics's average earnings over the past couple of years, and its industry performance. … See our latest analysis for Biomark Diagnostics Did 20B's recent earnings growth beat the long-term trend and the industry?
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allows for cancer detection, monitoring, and assessing treatment. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.